治疗C5抑制剂avacincaptad pegol治疗地理缩:一个全面的审查
Carl J Danzig1,2, Arshad M Khanani3,4, Anat Loewenstein5
1Rand Eye Institute, Deerfield Beach, FL 33064, USA.
Immunotherapy
|July 29, 2024
概括
地理缩 (GA) 是视力丧失的主要原因. 阿瓦辛卡帕达皮戈尔 (Avacincaptad pegol,简称ACP) 是FDA批准的一种治疗方法,可以减少GA患者的严重视力丧失.
科学领域:
- 眼科医生 眼科 眼科
- 视网膜疾病 视网膜疾病
- 药物开发 药物开发
背景情况:
- 地理缩 (GA) 是不可逆转的中央视力丧失的主要原因.
- 目前,GA还没有治愈,严重影响患者的生活质量.
- GA涉及缩的视网膜病变,这可能会威胁到视,导致严重的视力损伤.
研究的目的:
- 对地理缩的阿瓦辛卡普塔德佩戈尔 (ACP) 的临床试验景观进行审查.
- 评估ACP在减少病变生长和维护视觉功能的有效性.
- 分析后期数据,表明ACP有潜力减轻GA患者严重视力损失的风险.
主要方法:
- 对评估avacincaptad pegol (ACP) 的临床试验的审查.
- 从临床研究中分析后期数据.
- 评估ACP对地理缩病变进展和视觉结果的影响.
主要成果:
- 阿瓦辛卡普塔德 (Avacincaptad pegol,简称ACP) 是FDA批准的治疗地理缩的药物.
- 新兴的治疗方法,包括ACP,显示出减缓GA病变增长的潜力.
- 后期分析表明,ACP可以降低GA患者严重视力丧失的风险.
结论:
- 阿瓦辛卡普塔德醇 (ACP) 代表了GA治疗的重大进展.
- 通过降低地理缩进展的速度,ACP可以帮助维护视觉功能.
- 进一步的研究和分析支持ACP在管理与GA相关的严重视力损失方面的作用.
更多相关视频
09:46Isolation, Culture, and Genetic Engineering of Mammalian Primary Pigment Epithelial Cells for Non-Viral Gene Therapy
Published on: February 26, 2021
3.2K
07:04Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
Published on: February 4, 2021
2.0K
相关概念视频
01:28Angle Closure Glaucoma: Treatment
463
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
463
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
01:27Open Angle Glaucoma: Treatment
420
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
420